Face Forward Aesthetics Expands Injectable Portfolio with Letybo
News related to:Face Forward Aesthetics · 2 min read
COLUMBUS, Ohio, Oct. 19, 2026 /CourierPR/ -- Face Forward Aesthetics, a nurse practitioner-led medical aesthetics practice serving Ohio, Pennsylvania, and Nevada, has expanded its injectable treatment portfolio with Letybo®, a neurotoxin developed by South Korean medical aesthetics company Hugel. The addition of Letybo, which is FDA-approved for the temporary improvement of moderate to severe frown lines between the eyebrows in adults, builds on Face Forward's longstanding relationship with Hugel as one of its early national partners.
The introduction of Letybo aligns with the company's commitment to personalized, provider-led care and its ongoing efforts to stay at the forefront of aesthetic innovation. As Korean beauty continues to shape global skincare and aesthetic trends, growing interest in slow aging and longevity reflects a shift toward more thoughtful, personalized approaches to beauty and wellness. Known as "K-Tox," Letybo is South Korea's leading neurotoxin, backed by more than 15 years of global clinical experience.
Hugel, established in 2001, is a global medical aesthetics company specializing in botulinum toxin products, hyaluronic acid dermal fillers, and other aesthetic solutions. With a growing international presence, Hugel is committed to advancing aesthetic medicine through research, innovation, and product development. The company has been a key partner for Face Forward Aesthetics, which was founded in 2018 and is headquartered in the Columbus area, with clinics across Ohio, Pennsylvania, and Nevada.
The addition of Letybo to Face Forward Aesthetics' portfolio underscores the company's dedication to offering a wide range of treatment options to its guests. Letybo is another FDA-approved neurotoxin option, supporting individualized treatment plans and allowing providers to further individualize treatment recommendations. The introduction of Letybo also builds on the company's existing relationship with Hugel, as one of its early national partners, and expands access to Letybo through its network of clinics.
Hugel's CEO and President, Carrie Strom, praised Face Forward Aesthetics for its commitment to personalized care and clinical excellence.
Ashley Ponce, Chief Operating Officer of Face Forward Aesthetics, emphasized the company's commitment to staying at the forefront of aesthetic innovation.
Ellie Metzger, Lead Nurse Practitioner at Face Forward Aesthetics, highlighted the benefits of Letybo, noting that some patients begin noticing results quickly.
Face Forward Aesthetics offers injectable treatments, advanced laser and skin-rejuvenation services, and facials, with an emphasis on clinical expertise, individualized treatment plans, and an approachable guest experience. The company's recent brand refresh, redesigned website, and expansion of advanced facial services further reinforce its commitment to nurse practitioner-led care, continued innovation, and an elevated guest experience.
Letybo, a neurotoxin developed by Hugel, has become South Korea's leading neurotoxin, backed by more than 15 years of global clinical experience. The addition of Letybo to Face Forward Aesthetics' portfolio supports the company's commitment to personalized care and clinical excellence, allowing providers to further individualize treatment recommendations. The company's recent brand refresh, redesigned website, and expansion of advanced facial services reinforce its commitment to nurse practitioner-led care, continued innovation, and an elevated guest experience.